Debut Biotech Raises $22.6M Series A to Commercialize High-Value Ingredients from Proprietary Cell-Free Biomanufacturing Platform
Novel ingredients bring unique advantages to cosmetic, food, and health and wellness markets in one of the largest Series A financing rounds in synthetic biology space
Biotech promises to be the future of chemical synthesis and is already used to manufacture numerous cosmetics and personal care ingredients. The Debut-DIC deal is on track to deliver not only a new source for cosmetics pigments but also to showcase a new sort of biotech platform.
Every day seems to bring a fundraising record and a new company launching in the biotech industry. Insider spoke with some of the smartest and most plugged-in venture capitalists in biotech to pinpoint the most exciting startups.
Food ingredients startups to watch, from rare sugars and prebiotic fibers to ‘cell-free’ biomanufacturing
From San Diego-based Debut Biotech, which is developing a range of high-value ingredients via a novel ‘cell-free’ biomanufacturing platform, to Virginia-based Bonumose, which has patented technology it claims could enable the “mass market adoption” of rare sugars.